Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 15/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9165088 | 0.92 | CA12 (0.47) | CYP19A1CA12CA2CA3CA6 | |
| SCHEMBL9165274 | 0.92 | ALDH1A1 (0.47) | CYP19A1CYP3A4CYP2C19ALDH1A1CYP2A6 | |
| SCHEMBL8767389 | 0.92 | CYP19A1 (0.41) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL9167057 | 0.90 | CYP19A1 (0.47) | CYP19A1ALDH1A1 | |
| SCHEMBL9159563 | 0.89 | KIF11 (0.47) | CYP19A1CYP3A4 | |
| SCHEMBL9158480 | 0.87 | CYP19A1 (0.37) | CYP19A1ALDH1A1 | |
| SCHEMBL9163503 | 0.86 | CYP19A1 (0.68) | CYP19A1CYP3A4CYP11B1CYP11B2CYP2C19 | |
| SCHEMBL1552746 | 0.84 | CYP19A1 (0.38) | CYP19A1TSHROPRD1 | |
| SCHEMBL9160207 | 0.83 | CYP19A1 (0.37) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL9163386 | 0.83 | AHR (0.38) | CYP19A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0907351-B2 | COSMETIC OR COSMETIC PREPARATION FOR SMOOTHING AND TIGHTENING THE SKIN IN THE CASE OF SUBCUTANEOUS FATTY TISSUE PROBLEMS, PARTICULARLY CELLULITE | KEYVEST GMBH (DE) | 2012-04-18 | — | — | EP | claimed |
| JP-4716728-B2 | — | — | 2011-07-06 | — | — | JP | claimed |
| EP-0236940-B3 | Alpha-heterocycle substituted tolunitriles | NOVARTIS AG (CH) | 2011-03-23 | — | — | EP | claimed |
| EP-1534265-B1 | COMBINATION OF AN AROMATASE INHIBITOR WITH A BISPHOSPHONATE | NOVARTIS AG (CH) | 2006-11-22 | — | — | EP | claimed |
| US-20060148772-A1 | Combination | EVANS ASTRID H | 2006-07-06 | — | — | US | claimed |
| US-20060069067-A1 | Combination of an aromatase inhibitor with a bisphosphonate | NOVARTIS PHARMACEUTICALS CORPORATION | 2006-03-30 | — | — | US | claimed |
| EP-1534265-A1 | COMBINATION OF AN AROMATASE INHIBITOR WITH A BISPHOSPHONATE | Novartis AG (CH) | 2005-06-01 | — | — | EP | claimed |
| WO-2004012728-A1 | COMBINATION OF AN AROMATASE INHIBITOR WITH A BISPHOSPHONATE | NOVARTIS AG (CH) | 2004-02-12 | — | — | WO | claimed |
| US-6245812-B1 | Treatment of hot flashes (flushing) using leucine alone or in combination with other branched chain amino acids | CHARLOTTE LABORATORIES, LLC | 2001-06-12 | — | — | US | claimed |
| US-5583128-A | ADMINISTERING A SIDE EFFECT REDUCED AROMATASE INHIBITOR | CIBA-GEIGY CORPORATION (US) | 1996-12-10 | — | — | US | claimed |
| US-5352795-A | Condensing triazolylmethylbenzonitrile with fluorobenzonitrile under basic conditions using alkali metal alkoxide | CIBA-GEIGY CORPORATION (US) | 1994-10-04 | — | — | US | claimed |
| EP-0236940-B1 | ALPHA-HETEROCYCLE SUBSTITUTED TOLUNITRILES | CIBA-GEIGY AG (CH) | 1993-09-22 | — | — | EP | claimed |
| WO-1992018132-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA COMTAINING A 5 ALPHA-REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 1992-10-29 | — | — | WO | claimed |
| US-4978672-A | Alpha-heterocyclc substituted tolunitriles | CIBA-GEIGY CORPORATION (US) | 1990-12-18 | — | — | US | claimed |
| CN-118058233-B | Batch production method for improving sow farrowing rate or live birth number | 中国农业大学 | 2024-07-16 | — | — | CN | disclosed |
| CN-118058233-A | Batch production method for improving sow farrowing rate or live birth number | 中国农业大学 | 2024-05-24 | — | — | CN | disclosed |
| US-11974977-B2 | Composition and uses for influencing hair growth | LUCOLAS—M.D. LTD (GB) | 2024-05-07 | — | — | US | disclosed |
| US-4937250-A | AROMATASE ENZYME INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1990-06-26 | — | — | US | disclosed |
| US-4749713-A | Alpha-heterocycle substituted tolunitriles | CIBA-GEIGY CORPORATION (US) | 1988-06-07 | — | — | US | disclosed |
| EP-0236940-A2 | Alpha-heterocycle substituted tolunitriles | CIBA-GEIGY AG (CH) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148772-A1 | Combination | ERBB2, EGFR, ERBB3 | CYP19A1 5/4885CYP3A4 1330/4885CYP11B1 156/4885 |
| US-20060069067-A1 | Combination of an aromatase inhibitor with a bisphosphonate | CYP19A1, BRCA1, SHBG | CYP19A1 1/4885CYP3A4 909/4885CYP11B1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.